| scholarly article | Q13442814 |
| P50 | author | Winfried Rief | Q22087747 |
| P2093 | author name string | A J Barsky | |
| B K Doering | |||
| U Bingel | |||
| U Schweiger | |||
| R Schwarting | |||
| M Wöhr | |||
| P2860 | cites work | Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia | Q22241430 |
| Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy | Q23791313 | ||
| Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: a randomized controlled trial | Q23912881 | ||
| Induction of fear extinction with hippocampal-infralimbic BDNF | Q41891373 | ||
| Fear erasure in mice requires synergy between antidepressant drugs and extinction training. | Q41967620 | ||
| Facilitation of serotonin signaling by SSRIs is attenuated by social isolation. | Q42088160 | ||
| Catatonic behavior induced by haloperidol, increased by retesting and elicited without drug in rats | Q42260726 | ||
| Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs. | Q42523089 | ||
| Long-term plasticity of visually evoked potentials in humans is altered in major depression | Q42609601 | ||
| Adult neurogenesis is reduced in the dorsal hippocampus of rats displaying learned helplessness behavior | Q42917730 | ||
| A follow-up fMRI study of a transferable placebo anxiolytic effect. | Q43431905 | ||
| Morphometric study of synaptic patterns in the rat caudate nucleus and hippocampus under haloperidol treatment | Q43655651 | ||
| Increased responsiveness of dopamine to atypical, but not typical antipsychotics in the medial prefrontal cortex of rats reared in isolation | Q43731980 | ||
| Long-term antidepressant use and the risk of type 2 diabetes mellitus: a population-based, nested case-control study in Taiwan | Q43904706 | ||
| Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. | Q43918852 | ||
| Atypical neuroleptics stimulate neurogenesis in adult rat brain | Q44059818 | ||
| Effects of working memory training on functional connectivity and cerebral blood flow during rest | Q44356354 | ||
| Context-dependent catalepsy intensification is due to classical conditioning and sensitization | Q44616700 | ||
| Hippocampal volume and cell proliferation after acute and chronic clozapine or haloperidol treatment | Q44721396 | ||
| Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus | Q44793041 | ||
| Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. | Q44845263 | ||
| Chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine D2L receptors. | Q45072843 | ||
| Combination of fluoxetine and extinction treatments forms a unique synaptic protein profile that correlates with long-term fear reduction in adult mice | Q45358485 | ||
| Chronic treatment with fluoxetine prevents the return of extinguished auditory-cued conditioned fear | Q45391043 | ||
| Delayed BDNF alterations in the prefrontal cortex of rats exposed to prenatal stress: preventive effect of lurasidone treatment during adolescence. | Q46469284 | ||
| Changes of brain morphometry in first-episode, drug-naïve, non-late-life adult patients with major depression: an optimized voxel-based morphometry study. | Q46477700 | ||
| Dopaminergic modulation of the reward system in schizophrenia: a placebo-controlled dopamine depletion fMRI study | Q46594759 | ||
| Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress | Q46791939 | ||
| Treatment with olanzapine increases cell proliferation in the subventricular zone and prefrontal cortex | Q46888961 | ||
| Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis | Q46962136 | ||
| Repeated social defeat-induced depression-like behavioral and biological alterations in rats: involvement of cholecystokinin | Q46983162 | ||
| Post-extinction fluoxetine treatment prevents stress-induced reemergence of extinguished fear | Q47350191 | ||
| Expectation in perceptual decision making: neural and computational mechanisms | Q47718806 | ||
| Physical exercise down-regulated locomotor side effects induced by haloperidol treatment in Wistar rats | Q47927340 | ||
| The effects of isolated and enriched housing conditions on baseline and drug-induced behavioural responses in the male rat. | Q47979175 | ||
| Maintenance treatment with antipsychotic drugs for schizophrenia | Q24197902 | ||
| Exercise for depression | Q24198097 | ||
| Haloperidol versus placebo for schizophrenia | Q24202457 | ||
| Amitriptyline versus placebo for major depressive disorder | Q24202486 | ||
| Antidepressants versus placebo for depression in primary care | Q24239979 | ||
| Active placebos versus antidepressants for depression | Q24247474 | ||
| Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety | Q24617064 | ||
| Eye tracking of attention in the affective disorders: a meta-analytic review and synthesis | Q26822698 | ||
| Emotion circuits in the brain | Q27860733 | ||
| Is mood chemistry? | Q28237445 | ||
| Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder | Q28251587 | ||
| Antidepressant treatment outcome depends on the quality of the living environment: a pre-clinical investigation in mice | Q28487260 | ||
| Desvenlafaxine may accelerate neuronal maturation in the dentate gyri of adult male rats | Q28539344 | ||
| Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants | Q29547516 | ||
| Critical period plasticity in local cortical circuits | Q29617443 | ||
| Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus | Q29619400 | ||
| The contextual brain: implications for fear conditioning, extinction and psychopathology | Q30372063 | ||
| Prenatal antidepressant exposure: clinical and preclinical findings | Q30415540 | ||
| Lack of parvalbumin in mice leads to behavioral deficits relevant to all human autism core symptoms and related neural morphofunctional abnormalities | Q30416844 | ||
| Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine | Q30458533 | ||
| A novel application of the Intent to Attend assessment to reduce bias due to missing data in a randomized controlled clinical trial | Q30827408 | ||
| Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention | Q33397604 | ||
| Early exposure to haloperidol or olanzapine induces long-term alterations of dendritic form | Q33594620 | ||
| Adult neuroplasticity: more than 40 years of research | Q33634893 | ||
| Environmental enrichment induces behavioral recovery and enhanced hippocampal cell proliferation in an antidepressant-resistant animal model for PTSD. | Q33654216 | ||
| Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. | Q33814201 | ||
| Overgeneral autobiographical memory as a predictor of the course of depression: a meta-analysis. | Q33886319 | ||
| Effect of environmental cues on the behavioral efficacy of haloperidol, olanzapine, and clozapine in rats | Q33917898 | ||
| Reversal of hippocampal neuronal maturation by serotonergic antidepressants. | Q33929389 | ||
| Maximizing exposure therapy: an inhibitory learning approach | Q33968137 | ||
| Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease | Q34086449 | ||
| Stress coping stimulates hippocampal neurogenesis in adult monkeys | Q34093030 | ||
| Changes in brain function of depressed subjects during treatment with placebo | Q34107522 | ||
| Influence of enrichment on behavioral and neurogenic effects of antidepressants in Wistar rats submitted to repeated forced swim test | Q48156397 | ||
| Exercise for depression | Q48271591 | ||
| Haloperidol modulates midbrain-prefrontal functional connectivity in the rat brain | Q48287944 | ||
| Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: hemispheric asymmetry and reversal by fluoxetine treatment | Q48339731 | ||
| Striatal enlargement in rats chronically treated with neuroleptic. | Q48361967 | ||
| Synaptic rearrangements in medial prefrontal cortex of haloperidol-treated rats | Q48435138 | ||
| Effect of early life housing manipulation on baseline and drug-induced behavioural responses on neurochemistry in the male rat. | Q48628262 | ||
| Moving from efficacy to effectiveness in cognitive behavioral therapy for psychosis: a randomized clinical practice trial | Q48667903 | ||
| Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation | Q48714094 | ||
| Antidepressants differentially modify the extinction of an aversive memory task in female rats. | Q48736990 | ||
| Effects of sertraline on behavioral alterations caused by environmental enrichment and social isolation | Q48755595 | ||
| Exercise affects memory acquisition, anxiety-like symptoms and activity of membrane-bound enzyme in brain of rats fed with different dietary fats: impairments of trans fat. | Q48916727 | ||
| Effects of chronic exercise and treatment with the antipsychotic drug olanzapine on hippocampal volume in adult female rats | Q48923336 | ||
| Inhibition of adult hippocampal neurogenesis disrupts contextual learning but spares spatial working memory, long-term conditional rule retention and spatial reversal. | Q50761287 | ||
| Haloperidol conditioned catalepsy in rats: a possible role for D1-like receptors. | Q51847137 | ||
| Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiolog | Q51864697 | ||
| Reduced stress-sensitivity or increased reward experience: the psychological mechanism of response to antidepressant medication. | Q51890533 | ||
| The role of NMDA and AMPA/Kainate receptors in the consolidation of catalepsy sensitization. | Q51894194 | ||
| Nonpharmacological bases of drug tolerance and dependence. | Q52290167 | ||
| Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. | Q55053712 | ||
| Mechanisms involved in placebo and nocebo responses and implications for drug trials | Q85047394 | ||
| The hidden effects of blinded, placebo-controlled randomized trials: an experimental investigation | Q85237225 | ||
| Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis | Q86711108 | ||
| Glucocorticoids orchestrate divergent effects on mood through adult neurogenesis. | Q37013413 | ||
| Neuroplasticity in depressed individuals compared with healthy controls | Q37172753 | ||
| Individual differences in psychotic effects of ketamine are predicted by brain function measured under placebo | Q37338731 | ||
| Fluoxetine exposure during adolescence alters responses to aversive stimuli in adulthood | Q37479393 | ||
| Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis | Q37610143 | ||
| New perspectives on the neurodevelopmental effects of SSRIs | Q37645078 | ||
| The placebo response in pain and depression: in search of a common pathway | Q37663313 | ||
| Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. | Q37685313 | ||
| Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used. | Q37769036 | ||
| A meta-analysis of the magnitude of biased attention in depression. | Q37807012 | ||
| Utilizing placebo mechanisms for dose reduction in pharmacotherapy | Q37979359 | ||
| Neural mechanisms of social risk for psychiatric disorders | Q38002732 | ||
| Synaptic dysfunction in depression: potential therapeutic targets | Q38050123 | ||
| The placebo response in medicine: minimize, maximize or personalize? | Q38085499 | ||
| The prospective long-term course of adult depression in general practice and the community. A systematic literature review | Q38161156 | ||
| Drug approval and drug effectiveness | Q38170455 | ||
| Effects of antipsychotic D2 antagonists on long-term potentiation in animals and implications for human studies | Q38211233 | ||
| Adult neurogenesis: beyond learning and memory | Q38253880 | ||
| Chronic fluoxetine treatment suppresses plasticity (long-term potentiation) in the mature rodent primary auditory cortex in vivo | Q38293213 | ||
| Amygdala-frontal couplings characterizing SSRI and placebo response in social anxiety disorder | Q38433714 | ||
| Short-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: a randomized, placebo-controlled trial | Q38479840 | ||
| Neuro-Bio-Behavioral Mechanisms of Placebo and Nocebo Responses: Implications for Clinical Trials and Clinical Practice | Q38540866 | ||
| Expectancies as core features of mental disorders | Q38545410 | ||
| Perineuronal nets protect fear memories from erasure | Q39279816 | ||
| Placebo in emotional processing--induced expectations of anxiety relief activate a generalized modulatory network | Q39365805 | ||
| Catalepsy intensifies context-dependently irrespective of whether it is induced by intermittent or chronic dopamine deficiency | Q40606115 | ||
| Placebo response in studies of major depression: variable, substantial, and growing | Q34122652 | ||
| The functional neuroanatomy of the placebo effect | Q34126324 | ||
| Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment | Q34210818 | ||
| The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey | Q34328733 | ||
| Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. | Q34351095 | ||
| Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. | Q34357875 | ||
| Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions. | Q34359440 | ||
| Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice | Q34363151 | ||
| BDNF in schizophrenia, depression and corresponding animal models | Q34385320 | ||
| Physical exercise-induced hippocampal neurogenesis and antidepressant effects are mediated by the adipocyte hormone adiponectin | Q34444287 | ||
| The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective | Q34453423 | ||
| Neurobiological mechanisms of the placebo effect. | Q34466524 | ||
| Linking Molecules to Mood: New Insight Into the Biology of Depression | Q34540304 | ||
| Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression | Q34589878 | ||
| Physical skill training increases the number of surviving new cells in the adult hippocampus | Q34598228 | ||
| A neurocomputational account of catalepsy sensitization induced by D2 receptor blockade in rats: context dependency, extinction, and renewal | Q34629593 | ||
| Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses | Q34634132 | ||
| Enhancement of cognitive function in models of brain disease through environmental enrichment and physical activity | Q34640013 | ||
| How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials | Q34733976 | ||
| The antidepressant fluoxetine restores plasticity in the adult visual cortex | Q34771195 | ||
| Modeling social influences on human health | Q34792716 | ||
| A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. | Q34893258 | ||
| Meta-analysis of the placebo response in antidepressant trials | Q34952811 | ||
| Plasticity of ocular dominance columns in monkey striate cortex | Q35005710 | ||
| Placebo eff ects in psychiatry: mediators and moderators | Q35207492 | ||
| Mind matters: placebo enhances reward learning in Parkinson's disease | Q35854824 | ||
| Genetic strain differences in learned fear inhibition associated with variation in neuroendocrine, autonomic, and amygdala dendritic phenotypes. | Q35892774 | ||
| Twenty-five year mortality of a community cohort with schizophrenia | Q36028183 | ||
| Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction | Q36155336 | ||
| Prenatal exposure to antidepressants and depressed maternal mood alter trajectory of infant speech perception | Q36336176 | ||
| Antipsychotic-associated neuronal changes in the brain: toxic, therapeutic, or irrelevant to the long-term outcome of schizophrenia? | Q36352679 | ||
| A model of placebo response in antidepressant clinical trials | Q36774011 | ||
| Plasticity in gray and white: neuroimaging changes in brain structure during learning | Q36864561 | ||
| The neurogenesis hypothesis of affective and anxiety disorders: are we mistaking the scaffolding for the building? | Q36972430 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neuroplasticity | Q849491 |
| brain | Q1073 | ||
| P304 | page(s) | 51-64 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Neuroscience & Biobehavioral Reviews | Q15709986 |
| P1476 | title | Rethinking psychopharmacotherapy: The role of treatment context and brain plasticity in antidepressant and antipsychotic interventions | |
| P478 | volume | 60 |
| Q26741515 | Aerobic Exercise as a Tool to Improve Hippocampal Plasticity and Function in Humans: Practical Implications for Mental Health Treatment |
| Q28066386 | Can Psychological Expectation Models Be Adapted for Placebo Research? |
| Q47604513 | Comparing watchful waiting with antidepressants for the management of subclinical depression symptoms to mild-moderate depression in primary care: a systematic review |
| Q47692217 | Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder |
| Q47693093 | Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder |
| Q64111658 | Music-Enhanced Analgesia and Antiseizure Activities in Animal Models of Pain and Epilepsy: Toward Preclinical Studies Supporting Development of Digital Therapeutics and Their Combinations With Pharmaceutical Drugs |
| Q52646032 | Novel treatment options in depression and psychosis. |
| Q30834455 | Preoperative optimization of patient expectations improves long-term outcome in heart surgery patients: results of the randomized controlled PSY-HEART trial |
| Q64075761 | Re-evaluation of Significance and the Implications of Placebo Effect in Antidepressant Therapy |
| Q47094519 | SSRI and Motor Recovery in Stroke: Reestablishment of Inhibitory Neural Network Tonus |
| Q57796687 | Serotonin Selective Reuptake Inhibitors (SSRIs) and Stroke |
| Q39181179 | Understanding the role of serotonin in psychiatric diseases |
Search more.